Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer ; volume:20 ; number:1 ; day:8 ; month:12 ; year:2022 ; pages:1-14 ; date:12.2022
BMC medicine ; 20, Heft 1 (8.12.2022), 1-14, 12.2022
- Creator
-
Zuo, Yi-Han
Gao, Wei-Na
Xie, Ya-Jia
Yang, Sheng-Yong
Zhou, Jin-Tai
Liang, Hai-Hai
Fan, Xing-Xing
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12916-022-02670-0
- URN
-
urn:nbn:de:101:1-2023021809141943200833
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zuo, Yi-Han
- Gao, Wei-Na
- Xie, Ya-Jia
- Yang, Sheng-Yong
- Zhou, Jin-Tai
- Liang, Hai-Hai
- Fan, Xing-Xing
- SpringerLink (Online service)
Other Objects (12)
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Brain Metastasis from EGFR ‐Mutated Non‐Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up‐Regulates PDL1 and Promotes Immune Escape
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
Exosomes: a new perspective in EGFR-mutated lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Brain Metastasis from EGFR ‐Mutated Non‐Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up‐Regulates PDL1 and Promotes Immune Escape
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
Exosomes: a new perspective in EGFR-mutated lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Brain Metastasis from EGFR ‐Mutated Non‐Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up‐Regulates PDL1 and Promotes Immune Escape
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study